Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
70
ADMA Quote, Financials, Valuation and Earnings
Last price:
$20.12
Seasonality move
:
0.07%
Day range:
$19.56 - $20.22
52-week range:
$13.50 - $25.67
Dividend yield:
0%
P/E ratio:
23.16x
P/S ratio:
9.93x
P/B ratio:
10.88x
Volume:
2.6M
Avg. volume:
3.7M
1-year change:
0.8%
Market cap:
$4.7B
Revenue:
$426.5M
EPS (TTM):
$0.85
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ADMA
ADMA Biologics, Inc.
|
$130.5M | $0.16 | 18.96% | -57.14% | $27.25 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$277.2M | $0.15 | 12.73% | -82.4% | $29.26 |
|
ALDX
Aldeyra Therapeutics, Inc.
|
-- | -$0.16 | -- | -47.25% | $9.67 |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$87M | -$0.09 | 53.91% | -88.43% | $31.63 |
|
EXEL
Exelixis, Inc.
|
$590.2M | $0.67 | 7.5% | 59.24% | $44.94 |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$58.7M | -- | 11.45% | -- | $11.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ADMA
ADMA Biologics, Inc.
|
$19.72 | $27.25 | $4.7B | 23.16x | $0.00 | 0% | 9.93x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$25.88 | $29.26 | $4.4B | 16.65x | $0.00 | 0% | 4.16x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
$4.87 | $9.67 | $293M | -- | $0.00 | 0% | -- |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$29.96 | $31.63 | $3.7B | -- | $0.00 | 0% | 12.03x |
|
EXEL
Exelixis, Inc.
|
$44.01 | $44.94 | $11.8B | 18.53x | $0.00 | 0% | 5.50x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$5.27 | $11.75 | $311.4M | -- | $0.00 | 0% | 1.46x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -2.565 | 2.38% | 3.53x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.330 | 1.52% | 2.70x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
23.99% | 1.936 | 4.95% | 2.64x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
41.85% | -0.694 | 5.02% | 3.07x |
|
EXEL
Exelixis, Inc.
|
7.55% | 0.460 | 1.59% | 3.47x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
2.29% | 0.085 | 3.7% | 2.92x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALDX
Aldeyra Therapeutics, Inc.
|
-$63.7K | -$8M | -53.75% | -66.61% | -- | -$7M |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$90.5M | $8.5M | -15.75% | -29.4% | 8.59% | -$1.8M |
|
EXEL
Exelixis, Inc.
|
$579.2M | $256.4M | 28.73% | 31.26% | 42.89% | $288.8M |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$51.6M | -$31.3M | -16.2% | -16.55% | -55.61% | -$31.8M |
ADMA Biologics, Inc. vs. Competitors
-
Which has Higher Returns ADMA or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of 27.14% compared to ADMA Biologics, Inc.'s net margin of 25.76%. ADMA Biologics, Inc.'s return on equity of 58.71% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About ADMA or ACAD?
ADMA Biologics, Inc. has a consensus price target of $27.25, signalling upside risk potential of 38.19%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $29.26 which suggests that it could grow by 13.07%. Given that ADMA Biologics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe ADMA Biologics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ADMAADMA Biologics, Inc.4 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is ADMA or ACAD More Risky?
ADMA Biologics, Inc. has a beta of 0.433, which suggesting that the stock is 56.749% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.982%.
-
Which is a Better Dividend Stock ADMA or ACAD?
ADMA Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADMA or ACAD?
ADMA Biologics, Inc. quarterly revenues are $134.2M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. ADMA Biologics, Inc.'s net income of $36.4M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, ADMA Biologics, Inc.'s price-to-earnings ratio is 23.16x while ACADIA Pharmaceuticals, Inc.'s PE ratio is 16.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics, Inc. is 9.93x versus 4.16x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADMAADMA Biologics, Inc.9.93x 23.16x $134.2M $36.4M ACADACADIA Pharmaceuticals, Inc.4.16x 16.65x $278.6M $71.8M
-
Which has Higher Returns ADMA or ALDX?
Aldeyra Therapeutics, Inc. has a net margin of 27.14% compared to ADMA Biologics, Inc.'s net margin of --. ADMA Biologics, Inc.'s return on equity of 58.71% beat Aldeyra Therapeutics, Inc.'s return on equity of -66.61%.
Company Gross Margin Earnings Per Share Invested Capital ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M -
What do Analysts Say About ADMA or ALDX?
ADMA Biologics, Inc. has a consensus price target of $27.25, signalling upside risk potential of 38.19%. On the other hand Aldeyra Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 98.49%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than ADMA Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ADMAADMA Biologics, Inc.4 0 0 ALDXAldeyra Therapeutics, Inc.5 0 0 -
Is ADMA or ALDX More Risky?
ADMA Biologics, Inc. has a beta of 0.433, which suggesting that the stock is 56.749% less volatile than S&P 500. In comparison Aldeyra Therapeutics, Inc. has a beta of 0.831, suggesting its less volatile than the S&P 500 by 16.879%.
-
Which is a Better Dividend Stock ADMA or ALDX?
ADMA Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aldeyra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics, Inc. pays -- of its earnings as a dividend. Aldeyra Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADMA or ALDX?
ADMA Biologics, Inc. quarterly revenues are $134.2M, which are larger than Aldeyra Therapeutics, Inc. quarterly revenues of --. ADMA Biologics, Inc.'s net income of $36.4M is higher than Aldeyra Therapeutics, Inc.'s net income of -$7.7M. Notably, ADMA Biologics, Inc.'s price-to-earnings ratio is 23.16x while Aldeyra Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics, Inc. is 9.93x versus -- for Aldeyra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADMAADMA Biologics, Inc.9.93x 23.16x $134.2M $36.4M ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M
-
Which has Higher Returns ADMA or ARQT?
Arcutis Biotherapeutics, Inc. has a net margin of 27.14% compared to ADMA Biologics, Inc.'s net margin of 7.47%. ADMA Biologics, Inc.'s return on equity of 58.71% beat Arcutis Biotherapeutics, Inc.'s return on equity of -29.4%.
Company Gross Margin Earnings Per Share Invested Capital ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M ARQTArcutis Biotherapeutics, Inc.91.25% $0.06 $271.8M -
What do Analysts Say About ADMA or ARQT?
ADMA Biologics, Inc. has a consensus price target of $27.25, signalling upside risk potential of 38.19%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $31.63 which suggests that it could grow by 5.56%. Given that ADMA Biologics, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ADMAADMA Biologics, Inc.4 0 0 ARQTArcutis Biotherapeutics, Inc.5 1 0 -
Is ADMA or ARQT More Risky?
ADMA Biologics, Inc. has a beta of 0.433, which suggesting that the stock is 56.749% less volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.693, suggesting its more volatile than the S&P 500 by 69.345%.
-
Which is a Better Dividend Stock ADMA or ARQT?
ADMA Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics, Inc. pays -- of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADMA or ARQT?
ADMA Biologics, Inc. quarterly revenues are $134.2M, which are larger than Arcutis Biotherapeutics, Inc. quarterly revenues of $99.2M. ADMA Biologics, Inc.'s net income of $36.4M is higher than Arcutis Biotherapeutics, Inc.'s net income of $7.4M. Notably, ADMA Biologics, Inc.'s price-to-earnings ratio is 23.16x while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics, Inc. is 9.93x versus 12.03x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADMAADMA Biologics, Inc.9.93x 23.16x $134.2M $36.4M ARQTArcutis Biotherapeutics, Inc.12.03x -- $99.2M $7.4M
-
Which has Higher Returns ADMA or EXEL?
Exelixis, Inc. has a net margin of 27.14% compared to ADMA Biologics, Inc.'s net margin of 32.38%. ADMA Biologics, Inc.'s return on equity of 58.71% beat Exelixis, Inc.'s return on equity of 31.26%.
Company Gross Margin Earnings Per Share Invested Capital ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M EXELExelixis, Inc.96.89% $0.70 $2.3B -
What do Analysts Say About ADMA or EXEL?
ADMA Biologics, Inc. has a consensus price target of $27.25, signalling upside risk potential of 38.19%. On the other hand Exelixis, Inc. has an analysts' consensus of $44.94 which suggests that it could grow by 2.12%. Given that ADMA Biologics, Inc. has higher upside potential than Exelixis, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Exelixis, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ADMAADMA Biologics, Inc.4 0 0 EXELExelixis, Inc.9 9 0 -
Is ADMA or EXEL More Risky?
ADMA Biologics, Inc. has a beta of 0.433, which suggesting that the stock is 56.749% less volatile than S&P 500. In comparison Exelixis, Inc. has a beta of 0.400, suggesting its less volatile than the S&P 500 by 59.967%.
-
Which is a Better Dividend Stock ADMA or EXEL?
ADMA Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exelixis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics, Inc. pays -- of its earnings as a dividend. Exelixis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADMA or EXEL?
ADMA Biologics, Inc. quarterly revenues are $134.2M, which are smaller than Exelixis, Inc. quarterly revenues of $597.8M. ADMA Biologics, Inc.'s net income of $36.4M is lower than Exelixis, Inc.'s net income of $193.6M. Notably, ADMA Biologics, Inc.'s price-to-earnings ratio is 23.16x while Exelixis, Inc.'s PE ratio is 18.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics, Inc. is 9.93x versus 5.50x for Exelixis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADMAADMA Biologics, Inc.9.93x 23.16x $134.2M $36.4M EXELExelixis, Inc.5.50x 18.53x $597.8M $193.6M
-
Which has Higher Returns ADMA or VNDA?
Vanda Pharmaceuticals, Inc. has a net margin of 27.14% compared to ADMA Biologics, Inc.'s net margin of -40.15%. ADMA Biologics, Inc.'s return on equity of 58.71% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.
Company Gross Margin Earnings Per Share Invested Capital ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M -
What do Analysts Say About ADMA or VNDA?
ADMA Biologics, Inc. has a consensus price target of $27.25, signalling upside risk potential of 38.19%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 122.96%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than ADMA Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ADMAADMA Biologics, Inc.4 0 0 VNDAVanda Pharmaceuticals, Inc.3 1 0 -
Is ADMA or VNDA More Risky?
ADMA Biologics, Inc. has a beta of 0.433, which suggesting that the stock is 56.749% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.308%.
-
Which is a Better Dividend Stock ADMA or VNDA?
ADMA Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADMA or VNDA?
ADMA Biologics, Inc. quarterly revenues are $134.2M, which are larger than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. ADMA Biologics, Inc.'s net income of $36.4M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, ADMA Biologics, Inc.'s price-to-earnings ratio is 23.16x while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics, Inc. is 9.93x versus 1.46x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADMAADMA Biologics, Inc.9.93x 23.16x $134.2M $36.4M VNDAVanda Pharmaceuticals, Inc.1.46x -- $56.3M -$22.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
64
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
